Core Viewpoint - ImmunityBio (IBRX) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a quarterly loss of $0.12 per share, reflecting a 40% improvement from the previous year, and revenues expected to reach $15.69 million, a staggering increase of 39,125% from the same quarter last year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 1.45% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for ImmunityBio is lower than the consensus estimate, resulting in an Earnings ESP of -2.85%, suggesting a bearish outlook [10][11]. - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [8]. Historical Performance - In the last reported quarter, ImmunityBio was expected to post a loss of $0.26 per share but actually reported a loss of $0.15, resulting in a positive surprise of 42.31% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [13]. Comparative Industry Analysis - Pacira (PCRX), another player in the biomedical and genetics industry, is expected to report earnings of $0.57 per share, reflecting an 8.1% decline year-over-year, with revenues projected at $174.96 million, a 4.7% increase [17]. - Pacira's consensus EPS estimate has remained unchanged over the last 30 days, but it has an Earnings ESP of 34.51%, indicating a strong likelihood of beating the consensus estimate [18].

Wall Street expects a year-over-year increase in earnings on lower revenues when Golden Entertainment (GDEN) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 8 ...

Company Overview - Inter & Co. Inc. (INTR) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.12, reflecting a change of +33.3% [3] - Revenues are anticipated to reach $327.02 million, which is a 15.6% increase from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent changes in analyst views [10] Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - Inter & Co. Inc. currently holds a Zacks Rank of 2, making it challenging to predict an earnings beat conclusively [11] Historical Performance - In the last reported quarter, Inter & Co. Inc. exceeded the consensus EPS estimate of $0.10 by delivering $0.11, resulting in a surprise of +10% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Industry Context - In the Zacks Financial - Miscellaneous Services industry, HA Sustainable Infrastructure Capital (HASI) is expected to post earnings of $0.64 per share, indicating a year-over-year decline of -5.9% [17] - HASI's revenue is projected to be $33 million, down 21.3% from the previous year [17] - The consensus EPS estimate for HASI has been revised 0.8% higher in the last 30 days, but a lower Most Accurate Estimate results in an Earnings ESP of -3.91% [18]

Wall Street expects a year-over-year increase in earnings on higher revenues when Century Therapeutics, Inc. (IPSC) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

Ironwood Pharmaceuticals (IRWD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

The market expects Kenvue (KVUE) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better than ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Nektar Therapeutics (NKTR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the ...

Core Viewpoint - Onto Innovation (ONTO) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with earnings expected to be $1.47 per share, reflecting a 24.6% increase, and revenues projected at $264.96 million, up 15.8% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for May 8, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 1.07% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent estimate revisions may provide more accurate insights into the company's earnings potential [5][6]. - A negative Earnings ESP of -1.09% indicates that analysts have become bearish on Onto Innovation's earnings prospects, compounded by a Zacks Rank of 4, making it challenging to predict an earnings beat [10][11]. Historical Performance - Onto Innovation has a history of beating consensus EPS estimates, having done so in the last four quarters, including a surprise of +8.63% in the last reported quarter [12][13]. Conclusion - Despite the historical performance of beating estimates, Onto Innovation does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors before making investment decisions [14][16].

Duke Energy Corporation (DUK) is scheduled to release its first-quarter 2025 results on May 6, before market open.The company delivered an earnings surprise of 3.11% in the last reported quarter. Moreover, DUK holds a four-quarter average earnings surprise of 4.30%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Let’s discuss the factors that are likely to be reflected in the upcoming quarterly results.Factors at Play Ahead of DUK’s Q1 ResultsThe majority of DUK’s service territori ...

Core Insights - Linde reported $8.11 billion in revenue for Q1 2025, a year-over-year increase of 0.2%, with an EPS of $3.95 compared to $3.75 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $8.26 billion by 1.77%, while the EPS exceeded the consensus estimate of $3.93 by 0.51% [1] Financial Performance - Revenue by region: - Americas: $3.67 billion, a 3% increase year-over-year, below the average estimate of $3.73 billion [4] - EMEA: $2.03 billion, a 2.9% decrease year-over-year, below the average estimate of $2.14 billion [4] - Other: $311 million, a 2.5% decrease year-over-year, below the average estimate of $319.40 million [4] - Engineering: $565 million, a 4.8% increase year-over-year, slightly below the average estimate of $571.95 million [4] - APAC: $1.54 billion, a 3.3% decrease year-over-year, below the average estimate of $1.57 billion [4] Stock Performance - Linde's shares have returned -3.5% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]